Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Takes $2.46 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the first quarter, HoldingsChannel.com reports. The fund bought 200,000 shares of the company’s stock, valued at approximately $2,457,000. Syndax Pharmaceuticals comprises about 1.3% of Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group’s holdings, making the stock its 18th largest holding.

Other institutional investors also recently modified their holdings of the company. Soleus Capital Management L.P. lifted its holdings in Syndax Pharmaceuticals by 128.4% in the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company’s stock valued at $32,944,000 after acquiring an additional 1,401,016 shares during the period. Sphera Funds Management LTD. raised its stake in Syndax Pharmaceuticals by 33.5% during the 4th quarter. Sphera Funds Management LTD. now owns 1,381,241 shares of the company’s stock valued at $18,260,000 after purchasing an additional 346,395 shares during the period. Granahan Investment Management LLC raised its stake in Syndax Pharmaceuticals by 36.2% during the 4th quarter. Granahan Investment Management LLC now owns 905,322 shares of the company’s stock valued at $11,968,000 after purchasing an additional 240,557 shares during the period. Octagon Capital Advisors LP bought a new stake in Syndax Pharmaceuticals during the 4th quarter valued at approximately $11,951,000. Finally, Northern Trust Corp raised its stake in Syndax Pharmaceuticals by 7.5% during the 4th quarter. Northern Trust Corp now owns 792,750 shares of the company’s stock valued at $10,480,000 after purchasing an additional 55,144 shares during the period.

Syndax Pharmaceuticals Trading Up 0.3%

Shares of SNDX stock traded up $0.03 on Friday, reaching $9.70. 38,799 shares of the company’s stock were exchanged, compared to its average volume of 1,856,396. The company has a current ratio of 5.80, a quick ratio of 5.75 and a debt-to-equity ratio of 1.53. The company’s fifty day simple moving average is $9.91 and its 200 day simple moving average is $12.21. The stock has a market capitalization of $834.25 million, a PE ratio of -2.51 and a beta of 0.70. Syndax Pharmaceuticals, Inc. has a 52 week low of $8.58 and a 52 week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million during the quarter, compared to analyst estimates of $15.88 million. Syndax Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 757.53%. Syndax Pharmaceuticals’s revenue was up 1900.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.85) EPS. As a group, analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SNDX. JPMorgan Chase & Co. lifted their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 20th. Wall Street Zen upgraded Syndax Pharmaceuticals to a “sell” rating in a report on Tuesday, May 6th. The Goldman Sachs Group initiated coverage on Syndax Pharmaceuticals in a report on Thursday, July 10th. They set a “buy” rating and a $18.00 price target for the company. Guggenheim restated a “buy” rating and set a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. Finally, Scotiabank lifted their target price on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a “sector perform” rating in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.10.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).